speakers - springer978-1-4684-8944... · 2017-08-24 · alternate pathway of, 26 assay of c3, c4...

SPEAKERS

G. Andres, Buffalo, USA J.F. Bach, Paris, France F.C. Berthoux, Saint-Etienne,

France V. Bonomini, Bologna, Italy M. Broyer, Paris, France M. Camey, Suresnes, France G. Camussi, Turin, Italy R. Coppo, Turin, Italy E. Dormia, Lecco, Italy J. Egido, Madrid, Spain M. Fini, Bologna, Italy H. Fleisch, Berne, Switzerl&ld L. Giuliani, Genova, Italy J. Hannappel, Aachen, West

Germany H. Kreis, Paris, France F. Linari, Turin, Italy

Q. Maggiore, Reggio Calabria, Italy

R. Maiorca, Brescia, Italy A. Martelli, Bologna, Italy G. Maschio, Verona, Italy L. Miano, Rome, Italy P. Michielsen, Leuven, Belgium R. Mongiorgi, Bologna, Italy M. Pavone-Macaluso, Palermo,

Italy G. Piccoli, Turin, Italy V. Pulini, Bologna, Italy L. Riva di Sanseverino, Bologna,

Italy A. Rousaud, Barcelona, Spain B. Van Damme, Leuven, Belgium A. Vercellone, Turin, Italy

469

INDEX

Acetazolamide, in treatment of uric lithiasis, 365

Acetohydroxamic acid, 419, 431, 439

Acidosis, renal tubular and hypercalciuria, 397

Acute post-streptococcal glomerulonephritis,

immune complexes level, 30,47 immune complexes mediated

tubulo interstitial nephritis in, 101-

role of IgE basophil/mastocyte system in, 17

role of neutrophils in, 17 Alkalinization of urine,

in cystine lithiasis, 381 in uric lithiasis, 365

Allopurinol, in calcium lithiasis, 278, 352,

447, 450 in uric lithiasis, 365

Alport's syndrome nephritogenic antigens in, 78

Aminoacids, urinary excretion, in diagnosis of renal calculi,

380 AMP,cyclic

in hyperparathyroidism, 317 in release reaction, 13 in renal hypercalciuria, 331

Angioscintigraphy, in staghorn lithiasis, 425

Antibiotics, in urinary infected lithiasis, 417, 437

Antibodies, anti-brush border, 106

anti-DNA, 49 anti-FC receptor, 126 anti glomerular basement

membrane, 16, 78, 184 anti tubular basement membrane,

96 dependent cell-mediated

cytotoxicity, 123, 126 presensitization to HLA-A, Band

C donor antigens, 121 Antigens,

in human glomerulonephritis, 37 in human vasculitis, 67

Antiinflammatory drugs, and therapy of glomerulonephritis,

153 corticosteroids, 159, See also

corticosteroids Autotransplantation,

kidney, 429

parathyroid gland, 323

Bacteria, lithiasis and urea splitting,

419, 432, 447

urinary, 412, 425 Basophils,

and inflammation, 13

degranulation of, 17

471

472

Berger's glomerulonephritis, and renal transplantation, 144 and treatment witn

indomethacin, 155 immune complexes level and, 30

42 level of circulating suppressor

T cells in, 30, 148 phenytoin treatment of, 196

Bladder lithiasis, chemical composition of, 231 epidemiological factors in, 230 incidence of, 216

Blood transfusions, effect on renal transplantation

survival, 141 Bone histology,

in calcium lithiasis, 331 in hyperparathyroidism, 319

Brandt's test, 396 Britton's index, 416

Calcium lithiasis, 449 allopurinol in, 278, 352, 447,

450 bone histology in, 332 chemical composition of, 341 crystalluria in, 255 diet in, 328, 446 fluid intake in, 328 intestinal ~bsorption, 328, 338 renal handling of, 330 thiazide in, 257, 341, 419,

444, 450 urinary calcium/creatinine

ratio, 338, 444 urinary calcium excretion,

337, 349, 353 vitamin Din, 329

Calcium oxalate lithiasis, See oxalate lithiasis

INDEX

Calcium phosphate lithiasis, See phosphate lithiasis

Calculi, bladder, 216 calcium oxalate, 345, See also

oxalate lithiasis calcium phosphocarbonate, 339,

See also phosphatic lithiasis

chemical composition of, 341 crystalline composition of, 241

scanning electron microscopy, 243

x ray diffraction, 236, 242 cystine, 375, See also cystine

lythiasis epidemiological factors of, 213 geographic distribution of, 220 in children, 389 pathogenesis, 262

dietary factors, 228 diseases, 225 hypercalciuria, 337, 450 hyperoxaluria, 345 hyperparathyroidism, 313 hyperuricuria, 363 inhibitors, 275, 301, 332 promoters, 243, 277

soft, 403 urate ammonium, 215 uric acid, 357, See also uric

lithiasis urinary,

aminoacids excretion and, 380 calcium creatinine ratio, 338

444 crystalluria, 251 infection, 379, 405, 412, 447

urodynamic investigations, 261 xanthine, 394

INDEX

Cell-mediated,

antibody dependent

cytotoxicity, 123, 126

vasculitis, 65

Churg-Strauss granulomatosis, 60

Citrate, in urinary lithiasis,

282, 285, 307

Colloid protectors, 284

Complement,

activation of, 10, 26, 97

alternate pathway of, 26

assay of C3, C4 and B

components of, 27

assay of C3 nephritic factor,

28

classical pathway of, 26

common pathway of, 26

C3b and PMN in phagocytosis, 12

C5a anaphylotoxin and PMN, 11

dependent cytotoxicity, 126

hereditary deficiences, 30

in acute post-streptococcal

glomerulonephritis, 28

in membrano-proliferative


in systemic lupus

erythematosus, 29

nephritic. factor, 25

properdin, 26

total complement hemolytic

activity, 27

Corticosteroids,

and cryopheresis, 187

antiinflammatory and immuno

suppressive mechanisms

of, 160

in focal sclerosing


in membrano-proliferative


in membranous glomerulo-

nephritis, 171

473

Corticosteroids (cont'd)

in minimal change


in rapidly progressive


Crohn's disease, and oxaluria, 348

Cryoglobulinemia, essential mixed,

cryopheresis and, 186

cryoglobulins in, 186

cyclophosphamide in, 187

immune complexes mediated

tubulo-interstitial

nephritis in, 101

plasmapheresis and, 184

rheumatoid factor in, 185, 188

Cryoglobulins,

in essential mixed

cryoglobulinemia, 186

in human vasculitis, 69

Cryopheresis, 186

corticosteroids and immuno

suppressive agents and, 187

Crystal aggregation,

dendritism, 246

gemination, 246

inhibition of, 283, 285, 301, 332

promotion of, 243, 262, 277

Crystal growth,

epitaxial, 277, 303

inhibition of, 278, 284" 301, 332

promotion of, 243, 277

Cyclophosphamide,

in essential mixed

cryoglobulinemia, 187

in idiopathic glomerulonephritis,

166

Cystine lithiasis,

~-mercaptopropionylglycine in,

381, 437

diagnosis of, 377

diet in, 381

d-penicillamine in, 386, 447

Cystine lithiasis (cont'd) genetics of, 377 in children, 396 incidence of, 224, 375 kidney transplantation and, 144 litholysis in, 383, 384, 460 pathogenesis of, 376 urinary aminoacids in, 380

Cytotoxicity, antibody dependent cell

mediated, 123, 126 complement-dependent, 126 complement-dependent against

donor B cells, 126 lymphocyte-mediated, 123, 126

Dendritism and pathogenesis of renal lithiasis, 246

Depot dense glomerulonephritis, level of circulating suppressor

T cells in, 148 Dialysis,

early treatment and renal transplantation, 142

Diet, in calcium lithiasis, 328 in cystine lithiasis, 381 in primary bladder lithiasis,

Eluates, serum and renal, in cryoglobulinemia, 185

INDEX

in tubulointerstitial nephritis, 97

Epidemiology of urolithiasis, 213 factors,

dietary, 228 environmental, 226 familiar, 225 genetic, 223

geographic distribution of, 220 historical studies on, 215 incidence of, 217

Epitaxial growth, 277, 303

Fabry's disease, kidney transplantation and, 144

Fanconi's syndrome, antibodies antitubular basement membrane, 96

Fluid therapy, and epidemiology, 226 in calcium lithiasis, 328 in prophylaxis of urolithiasis,

448 Formation product in urinary

lithiasis, 279

229 Geminates in urinary lithiasis, 246 in pr~phylaxis of urolithiasis, Genetic of urolithiasis, 223

448 Glomerulonephritis, role of diet in urolithiasis,

228 Diphosphonates in urinary

lithiasis, 283, 285, 286, 289, ·307

DNA, anti DNA levels in systemic

lupus nephritis, 49 in human vasculitis, 68

D vitamin, See vitamin D

active and passive Heymann, 79 antibody anti-brush border in membranous, 107 antibody anti-tubular basement

membrane in, 96 complemen~ profile in acute post

streptococcal, 28 complement profile in membrano

proliferative, 29 complement profile in systemic

lupus erythematosus, 29

INDEX

Glomerulonephritis (cont'd)

complement system in the

pathogenesis of human, 25

corticosteroids in idiophatic,

159

epithelial crescent in, 17, 83


tubulo interstitial

nephritis in, 11

immunological treatment of, 147

immunopathology of, 10

indomethacin in the treatment

of primary, 153

level of circulating

suppre~sor T cells in

depot dense and in

Berger's, 148

pathogenesis of, 4

pathophysiology of

inflammation, 7


recurrence of glomerulo

nephritis after kidney

transplantation, 144

serum levels of immune

complexes in, 30, 42

subepithelial deposition of

immune complexes in, 84

Glomerulosclerosis focal,

and treatment with

indomethacin, 155

corticosteroids in, 168

immune complexes level in,

30, 42

kidney transplantation and,

144

Glycosaminoglycans, 283,286, 308

Goodpasture's syndrome,

plasmapheresis and

antibasement membrane

antibodies, 183

role of PMN in, 16

Gout, 363, 394, See also uric li thiasis

475

kidney transplantation and, 144

Hemolytic uremic syndrome,


Henoch-Schonlein purpura, 69

Hepatitis,

and periarteritis nodosa, 67

in "situ" formation of

immunocomplexes and B, 37

Heymann nephritis,

active and passive, 79, 103

Hydroxyadenine and uric stones, 396

Hydroxyurea, 432

Hypercalciuria,

absorptive, 329, 338, 450

and hyperoxaluria, 353

and hyperuricuria, 367

diagnosis of, 337, 442

in children, 397

intestinal ion exchangers in, 341

444

renal, 315, 329, 338, 450

renal tubular acidosis and, 397

resorptive, 331, 338

thiazide therapy in, 341, 419,

444, 450

type of stones in hypercalciuric

patients, 341

Hyperoxaluria,

allopurinol in, 353

and hypercalciuria, 353, 445


effect of low calcium intake,

ileal resection and

thiazide on, 346, 348, 349,

350, 351, 352

enteric, 348, 353

primary, 347, 348, 353, 392

pyridoxine and, 393

secondary, 394

Hyperoxaluria (cont'd)

thiazide in, 353

Hyperparathyroidism,

bone histology in, 319


peptic ulcer and, 316

primary, 315, 331, 397

secondary, 315, 329

surgical therapy of, 320

tertiary, 315

Hyperuricuria, 303, 363

and hypercalciuria, 367

Hypocomplementemia,

in human glomerulonephritis, 28

Hypoparathyroidism,

after parathyroidectomy, 323

Hypophosphatemia,

and calcium lithiasis, 329

in primary hyperparathyroidism,

317

Hypothermia,

of kidney in staghorn surgery,

417, 427

Immune complexes,

and tubulo interstitial

nephritis, 100

deposition in glomerulo

nephritis, 178

detection of, 30, 38, 39, 40,

41, 42

in "situ" formation, in

glomerulonephritis, 79,

37

in "situ" formation, in tubulo

interstitial nephritis,

102

interaction with PMN, 10

vascular deposition of, 60

Immunoglobulins,

IgE/basophil or mastocyte

system, 14, 17

INDEX

Immunoglobulins,

IgE mediated tubulo interstitial

nephritis, 107

role of IgE in human vasculitis,

67

serum IgA levels on Berger's


Immunosuppressive agents,

and cryopheresis, 187, 191

and idiopathic glomerulonephritis,

166

Indomethacin, treatment of


Infection, urinary tract,

and lithiasis, 341, 379, 398,

425, 441, 447

and therapy, 419, 432, 447

412

urea splitting bacteria and, 412,

425, 432

Inflammation,

basophils in, 13

cellular system in, 10

humoral systems in, 10

mononuclear phagocytes, 15

pathophysiology of, 7, 81

platelets in, 15

polymorphonuclear neutrophils in,

12

Interstitial nephritis, 91, See also

tubulo interstitial

nephritis

Lesch Nyhan syndrome, and uric

lithiasis, 36~, 396

Litholysis, 455

continuous perfusion, 456

in cystine calculi, 383, 384,

460

indications for, 462

in oxa~ic lithiasis, 460,

in soft renal lithiasis, 408,

460

INDEX

Litholysis (cont'd)

in struvite staghorn lithiasis,

417, 460

intermittent perfusion, 457

in uric lithiasis, 460

side effects of, 467

solutions for, 419, 461

Lupus erythematosus,

antibodies anti DNA in, 49

anti-idiotypic antibodies and, 15

complement profile in, 29

IC-PMN interaction in, 17

immune complexes level in, 30, 49 immune complexes mediated

tubulo interstitial

nephritis in, 101

plasmapheresis in, 184

role of platelets and PMN in,

18

Lymphocytes,

Band T cells in tubulo


99

cell-mediated lymphocyto

toxicity, 127

detection of transformed

lymphocytes in vivo, 127

inhibition of the mixed

lymphocyte reaction, 124

mediated cytotoxicity, 123, 128

mixea lymphocyte culture, 127

rosette forming cells, 127

suppressor T cells in depot

dense and in Berger's


Macrophage, inhibition factor,

126

477

Magnesium,

inhibitory

308

activity of, 282, 285,

in treatment of oxalic

lithiasis, 394

Major hystocompatibility system,

antibodies to HLA-A, Band C

donor antigens, 121

immune response gene (Ir) in

tubulo interstitial

nephritis, 100

Membrano proliferative

glomerulonephritis,

complement profile in, 29


immune complexes level in, 43

immune complexes mediate tubulo-

interstitial nephritis, 100


survival curve and treatment with

indomethacin, 155

Membranous glomerulonephritis,


immune complexes level in, 30, 42

a-Mercaptopropionylglycine, in the treatment of cystine

lithiasis, 381, 437

Mesangium, fuction of, 82 Methicillin, in tubulo interstitial

nephritis, 96

Methylene blue, inhibitory activity

of, 283, 286

Minimal change glomerulonephritis,


immune complexes level in, 30, 42

Monocytes,

in experimental vasculitis, 65

in inflammation,15

in tubulo interstitial nephritis,

96

Mucoprotein matrix stones, 403,

See also soft stones

478 INDEX

Myeloma, and plasmapheresis, 184 Parathyroid glands,

adenoma of, 315, 322

Nephritic factor, autotransplantation of, 323

assay of, 28 hyperplasia of, 315, 322

in activation of complement Parathyroid hormone,

system, 26 peripheral and selective assay, Nephritis, See glomerulonephritis 318

and tubulo interstitial

nephritis Nephroscopy, pyelocaliceal, 426

Nephrotic syndrome, cortieosteroids and, 165, 168

171, 174

indomethacin and, 154 penicillamine and, 386

Neutrophils, See polymorpho-nuclear neutrophils

Nordin's schedule, in diagnosis of hypercalciuria, 432

Oxalosis, kidney transplantation and, 144

primary, 347, 392

secondary, 348, 394

Oxalic acid, intestinal absorption of, 328,

347

urinary excretion of, 330, 347,

349

Oxalic lithiasis, and hypercalciuria, 341, 351

calcium oxalate product, 284

Crohn's disease and, 348

gallbladder stones and, 218

Penicillamine, and nephrotic syndrome, 386 in treatment of cystine lithiasis,

397, 447 Penicillin, in tubulo interstitial

nephritis, 98, 107 Periarteritis nodosa, hepatitis

antigen and, 67 Phenytoin, and treatment of Berger's


Phosphate cellulose, and absorptive hypercalciuria,

341, 443 'Phosphocalcic lithiasis, 337, See

also hypercalciuria calcium phosphate product, 279

familiar incidence in, 225 urinary inhibitors in, 278, 283

Plasmapheresis,


in tubulo interstitial nephritis,

110

Platelet activating factor,

and basophils, 17 and platelets, 14, 16

and polymorphonuclear neutrophils,

11 in children, 392 in immunologic injury of vessels,

incidence of, 217, 221, 225 62

inhibitors of, 284, 285 Platelets, in inflammation, 15

litholysis iq treatment of, 460 Polyethylene glycole (PEG),

Parathyroidectomy,

in hyperparathyroidism, 320

follow-up after, 324

detection of immune complexes by PEG test, 30, 41

INDEX

Polymorphonuclear neutrophils,

aggregation in human


aggregation in immunological

vasculitis, 60

and phagocytosis, 12

in acute post-streptococcal


in inflammation, 10, 12

in lupus erythematosus, 18

immune complexes interaction

with, 11, 42

Properdin,

in activation of complement

system, 26

Prostaglandins,

release reaction of, 14

Prostatic obstruction,

and uric lithiasis, 230

Pyelonephritis,

xantogranulomatous, 399, See

also tubulo interstitial

nephritis

Pyrophosphates, 5

inhibitory activity of, 281,

285, 286, 288, 305

Rapidly progressive

glomerulonephritis,


immune complexes level in, 43


tubulo interstitial

nephritis, 101



Recklinghausen disease, 316, See

also hyperparathyroidism

Renal,

biopsy, 406

calculi,_ See calculi

Renal (cont'd)

failure, and staghorn

lithiasis, 429

handling of calcium and uric

acid, 330

infection, See infection,

urinary tract

plasmatic flow, and staghorn

lithiasis, 416

scintigraphy, 416

479

transplant, See transplantation

Rheumatoid factor,

in essential mixed

cryoglobulinemia, 185, 188

in human vasculitis, 68

Scintigraphy, renal,

in diagnosis of staghorn

lithiasis, 416

Slow reacting substances,


Soft stones, 403

biochemical findings, 404

clinical feat~res, 405

litholysis of, 408, 460

surgical treatment, 407

Solid-phase C1Q test,

detection of immune complexes, 41 Solution for litholysis, 419, 461

Staghorn lithiasis, 423

and renal failure, 429


preoperative diagnostic

investigations, 425

surgical operations,

autotransplantation, 429

partial nephrectomy, 429

pyeloureteral plasty, 429

sinus approach, 426

transparenchymal approach, 426

Struvite lithiasis,


480

Struvite lithiasis (cont'd)

litholysis in, 417, 460

medical treatment of, 418, 419

pathogenetic factors of, 412

renal plasmatic flow in, 416

surgery in, 415, 423

vesical, 217

Tamm-Horsfall protein,

in immune complexes tubulo


104

in soft renal calculi, 405

Thiazide,

and crystalluria, 257

and urinary inhibitors, 306

288

in calcium lithiasis, 341, 353,

419, 434, 450

in uric lithiasis, 367

Thrombotic thrombocytopenic

. purpura,


Thromboxane,

induced aggregation of PMN, 11


Transplantation, renal

antibody anti-brush border in, 107

antibody anti-tubular basement

membrane in, 96

blood transfusions in, 141

cell mediated tubulo

interstitial nephritis

in, 105

contraindications for, ·144

early dialysis treatment and,

142

HLA matching in cadaver, 140

post-transplant immunologic

response, 126

INDEX

Transplantation (cont'd)

recipient presensitization to

donor antigens, 121

recipient presensitization to

non donor specific HLA

antigens, 124

surgical approach before, 141

tubular acidosis, and

hypercalciuria, 397

Tubulo-interstitial nephritis,

antibody anti-brush border and, , 106

antibody anti-tubular basement

membrane and, 96

cell mediated, 105

classification of, 94

IgE mediated, 107

immune complexes and, 100

in "situ"formation of immune

complexes in, 102

methicillin in, 96

pathogenesis of, 93

penicillin and, 98, 107

Urate ammonium lithiasis, 215

Urea splitting bacteria, 412, 425,

432

Uric acid,

.renal handling of, 330

Uric lithiasis,

bladder, 217

chemical composition in, 360, 396

in children, 394

incidence of, 215, 220, 357

litholysis in, 460

pathogenesis of, 363

thiazide and, 367

treatment of, 365

Urinary inhibitors,

acetohydroxamic acid, 419, 431

chemical estimation of, 278, 284,

304

INDEX

Urinary inhibitors (cont'd)

citrate, 282, 285, 307

diphosphonates, 275, 283, 286,

289, 307

glycosaminoglycans, 283, 286,

308

hydroxyurea, 432

magnesium, 282, 285, 308

pyrophosphates, 281, 285, 286,

288, 305

Urinary tract infection, See

infection

Urodynamic investigations,

physiology and pharmacology of

pyeloureteral system, 268

urinary flow and primary

nucleation, 263

urodynamic methods,

electromyography, 266

intrapelvic and intraureteral

pressure, 265

time distance diagram, 267

videodensitometry, 266

Vasculitis,

aggregation and release

reaction of

polymorphonuclear

neutrophils in, 61

cell mediated, 65

cryoglobulins and, 69

experimental models of, 58

hepatitis antigens and, 67

immunological aspects of

481

human, 66


rheumatoid factor and, 68

vascular deposition of immune

complexes, 59

Wegener and Churg-Strauss

granulomatosis, 70

Vitamin D,

calcium lithiasis and, 228, 329

in parathyroidectomized

patients, 324

secondary hyperparathyroidism

and, 315

Xanthine lithiasis, 394

X ray diffraction of calculi, 235,

242

Wegener granulomatosis,

immune complexes and, 70


speakers - springer978-1-4684-8944... · 2017-08-24 · alternate pathway of, 26 assay of c3, c4...

Documents